Novorapid (Insulin Aspart)

Insulin aspart, the active ingredient in Novorapid, is a rapid‑acting insulin analog presented as a clear solution for subcutaneous injection use. It lowers blood glucose by facilitating cellular uptake of glucose and is indicated for the management of diabetes mellitus in adults, adolescents, and children.

GNH USA supplies Novorapid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions and therapeutic markets.

Novorapid is a rapid‑acting insulin analog used to improve glycaemic control in diabetes mellitus. - Type 1 diabetes mellitus: provides rapid post‑prandial glucose control. - Type 2 diabetes mellitus: used as mealtime insulin to complement basal therapy. - Pediatric diabetes (age ≥2 years): enables flexible dosing for children with diabetes. - Gestational diabetes mellitus: may be employed when oral agents are insufficient to achieve target glucose levels.

Common Side Effects: - Hypoglycaemia: symptoms of low blood sugar such as sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight with chronic use. - Lipodystrophy: localized changes in subcutaneous fat tissue. - Headache: mild to moderate headache episodes. - Localised allergic reactions: rash or urticaria at the site.

Serious or Rare Side Effects: - Severe hypoglycaemia: prolonged or unconscious episodes requiring assistance. - Anaphylactic reaction: systemic allergic response with difficulty breathing or swelling. - Edema: abnormal fluid accumulation, especially in the lower extremities. - Serum sickness‑like reaction: fever, arthralgia, and rash. - Hypokalemia: low potassium levels that may affect cardiac function. - Acute pancreatitis: severe abdominal pain with elevated enzymes.

Patients and healthcare providers should consider the following precautions when using Novorapid. - Dose adjustment: tailor the dose based on blood glucose monitoring and carbohydrate intake. - Hypoglycaemia risk: educate patients on recognising and treating low‑blood‑sugar episodes. - Renal impairment: monitor closely and consider dose reduction in patients with reduced kidney function. - Pregnancy and lactation: use only if the anticipated benefit outweighs potential risks. - Drug interactions: review concomitant medications that may affect glucose levels. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Novorapid may interact with several medicines; awareness of the interaction level helps guide clinical decisions. Major Interactions (Avoid): - Concurrent use of beta‑blockers: may mask hypoglycaemia symptoms. - Combination with other insulin products: increases risk of severe hypoglycaemia. - Use with glucagon antagonists: may impair counter‑regulatory response to low glucose. Moderate Interactions (Monitor Closely): - Oral hypoglycaemic agents (e.g., sulfonylureas): additive glucose‑lowering effect. - Corticosteroids: may increase insulin requirement. - Thyroid hormones: may alter insulin metabolism and clearance.